Healthcare Industry News: HSMN NewsFeed
News Release - October 20, 2010
Salient Surgical’s New AQUAMANTYS3 System with Advanced Cutting and Hemostatic Sealing Device Proves Successful in First Surgical CasePORTSMOUTH, N.H.--(Healthcare Sales & Marketing Network)-- Salient Surgical announced today that the company has completed the first human cases in Europe using its new AQUAMANTYS®3 System. The new system includes a handpiece that combines for the first time Salient’s patented TRANSCOLLATION® technology for hemostatic sealing of soft tissue and bones with cutting capabilities.
Mr. David Harrison of Clementine Churchill Hospital in Harrow-on-the-Hill, England, was the first clinician to use the technology in spine surgery, where he performed a spinal fusion revision procedure, a lumbar disc replacement and a posterior lumbar interbody fusion, all of which were successful on many fronts. The revision patient lost approximately 150 ml of blood in a case where the typical blood loss is 800-1000 ml.
"I've seen a lot in thirty years of surgery, and I have to admit that I have become complacent when companies tell me that they have the next great thing," said Mr. Harrison following the surgery. "This is different." He continued, "I could instantly cut and seal the tissue without reaching for multiple devices. It also enabled us to eliminate the use of several blood management products typically used during these cases."
The AQUAMANTYS3 System employs TRANSCOLLATION technology, Salient’s proprietary combination of radiofrequency energy and saline that provides hemostatic sealing of soft tissue and bone. The new device takes the technology a step further by marrying this sealing feature with cutting abilities in one handpiece, strengthening its ability to reduce surgical time, perioperative blood loss and the need for blood transfusions. The AQUAMANTYS3 System is the subject of a pending 510(k) submission with the U.S. Food and Drug Administration and is not available in the US at this time.
“Surgeons who are using our TRANSCOLLATION technology have been asking us to add cutting capabilities because they know the value it will bring to the surgical procedures in their hospitals, and we see the impact it can have on their surgical outcomes,” stated Joseph F. Army, President and Chief Executive Officer of Salient. “We continue to develop new, innovative tools and look forward to providing this technology to our surgeons worldwide.”
About Salient Surgical Technologies
Salient Surgical Technologies, Inc. (www.salientsurgical.com) is a medical technology company that develops and markets advanced energy devices for use in surgical procedures. Salient's proprietary TRANSCOLLATION technology provides hemostatic sealing of soft tissue and bone. This allows surgeons to rapidly treat tissue at the surgical site to reduce blood loss and improve patient outcomes. Salient's products are currently used in orthopedic reconstruction, spine surgery, trauma procedures and surgical oncology. To date, TRANSCOLLATION technology has been used in over 490,000 surgical procedures.
Source: Salient Surgical Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.